Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 12:30:e943529.
doi: 10.12659/MSM.943529.

Efficacy and Safety of Sacubitril/Valsartan in Hemodialysis Patients with Chronic Heart Failure: A Retrospective Study at a Single Center

Zhuan'e Yao  1   2 , Pengbo Wang  1 , Qinjuan Fu  1 , Qiong Song  1 , Ai Liu  1 , Huan Li  1 , Wei Wang  1 , Peng Zhang  2
Affiliations

Efficacy and Safety of Sacubitril/Valsartan in Hemodialysis Patients with Chronic Heart Failure: A Retrospective Study at a Single Center

Zhuan'e Yao et al. Med Sci Monit. .

Abstract

BACKGROUND Heart failure and end-stage renal disease often coexist, and management of heart failure can be challenging in patients during hemodialysis. Sacubitril-valsartan (SV) is the first drug to receive regulatory approval for use in patients with chronic heart failure with reduced ejection fraction (HFrEF) and New York Heart Association (NYHA) classification II, III, or IV. This study aimed to evaluate the efficacy and safety of SV for use in chronic heart failure patients on maintenance hemodialysis (MHD). MATERIAL AND METHODS From September 2021 to October 2022, 28 patients on MHD with chronic heart failure at the hemodialysis center of Shaanxi Second Provincial People's Hospital were regularly followed. During the 12-week follow-up period, all patients were administered SV at doses of 100-400 mg per day. Biochemical indicators, echocardiographic parameters, life quality scores, and adverse events were evaluated. RESULTS We enrolled 28 patients. Compared with the baseline levels, NYHA class III in these patients treated with SV was significantly decreased from 60.71% to 32.14% (P<0.05), left ventricular ejection fraction (LVEF) was significantly improved from 44.29±8.92% to 53.32±7.88% (P<0.001), the Physical Component Summary (PCS) score was significantly improved from 40.0±6.41 to 56.20±9.86 (P<0.001), and the Mental Component Summary (MCS) score was significantly improved from 39.99±6.14 to 52.59±11.0 (P<0.001). CONCLUSIONS We demonstrated that SV improved NYHA classification and LVEF values of patients on MHD with chronic heart failure and also improved their quality of life.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared

Figures

Figure 1
Figure 1
Patient selection flow chart.
Figure 2
Figure 2
(A) Change in New York Heart Association (NYHA) Class after treatment with sacubitril/valsartan. (B) Change in left ventricular ejection fraction (LVEF) after treatment with sacubitril/valsartan. (C) Change in cardiac function after treatment with sacubitril/valsartan. (D) Change in quality of life after treatment with sacubitril/valsartan.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Roehm B, Gulati G, Weiner DE. Heart failure management in dialysis patients: Many treatment options with no clear evidence. Semin Dial. 2020;33(3):198–208. - PMC - PubMed
    1. Khan MS, Ahmed A, Greene SJ, et al. Managing heart failure in patients on dialysis: state-of-the-art review. J Card Fail. 2023;29(1):87–107. - PubMed
    1. Hou F, Jiang J, Chen J, et al. China collaborative study on dialysis: A multi-centers cohort study on cardiovascular diseases in patients on maintenance dialysis. BMC Nephrol. 2012;13:94. - PMC - PubMed
    1. Jhund PS, Petrie MC, Robertson M, et al. Heart failure hospitalization in adults receiving hemodialysis and the effect of intravenous iron therapy. JACC Heart Fail. 2021;9:518–27. - PubMed
    1. Bayard G, Da Costa A, Pierrard R, et al. Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation. Int J Cardiol Heart Vasc. 2019;25:100418. - PMC - PubMed

MeSH terms

-